ReviewLife (Basel, Switzerland)2022
Molecular Mechanisms of Action of Eugenol in Cancer: Recent Trends and Advancement.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Lesion size reduction in mouse model of endometriosis following clove (International journal of reproductive biomedicine · 2026Article
- Structural Modification of Selected Essential Oil Components for Potential Anticancer Applications: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Astragalus membranaceus polysaccharide (APs) and Eugenol: Multi-target Anti-inflammatory, Antioxidant, Antimicrobial, and anticancer effects validated by in Silico studies.Journal, genetic engineering & biotechnology · 2026Article
- Antioxidant Potential ofMolecules (Basel, Switzerland) · 2026Article
- Syzygium aromaticum L. (Clove): A Comprehensive Reveiw of Its Ethnopharmacological Uses and Pharmacological Activities.Chinese journal of integrative medicine · 2026Review
- Crocin and eugenol enhance radiosensitivity in oral squamous cell carcinoma cells via apoptotic pathways and cell cycle regulation. Type of study: in vitro.BMC complementary medicine and therapies · 2026Article
- TCMToxDB: a comprehensive database for the toxicological analysis of traditional Chinese medicines.Database : the journal of biological databases and curation · 2026Article
- New Phenylpropanoid fromCurrent pharmaceutical design · 2026Review
- Therapeutic Effect of Eugenol-Loaded Chitosan Nanoparticles AgainstInternational journal of biomaterials · 2026Article
- Neuroprotective Effects of Eugenol in Alzheimer's Disease: Mitigating Oxidative Stress, Inflammation and Amyloid Plaques.Current pharmaceutical design · 2026Review
- Chemical Composition, Biological Activity, and In VivoToxicity of Essential Oils Extracted from Mixtures of Plants and Spices.Molecules (Basel, Switzerland) · 2025Article
- Solubility prediction and cytotoxicity of lipidic microemulsion: HSPiP modeling and synergism with ciclopirox olamine.Scientific reports · 2025Article
- Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects.Food science & nutrition · 2025Review
- Water-Soluble Formulations of Curcumin and Eugenol Produced by Spray Drying.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Evaluating the Chemical Composition and Antitumor Activity ofInternational journal of molecular sciences · 2025Article
- Network Pharmacology and Molecular Dynamics Identified Potential Androgen Receptor-Targeted Metabolites inInternational journal of molecular sciences · 2025Article
- Article
- Monoterpenoid synergy: a new frontier in biological applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Herbs and their Active Constituents for Gastric Cancer and Related Problems - Preclinical and Clinical Studies.Current protein & peptide science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is, at present, among the leading causes of morbidity globally. Despite advances in treatment regimens for cancer, patients suffer from poor prognoses. In this context, the availability of vast natural resources seems to alleviate the shortcomings of cancer chemotherapy. The last decade has seen a breakthrough in the investigations related to the anticancer potential of dietary phytoconstituents. Interestingly, a handsome number of bioactive principles, ranging from phenolic acids, phenylpropanoids, flavonoids, stilbenes, and terpenoids to organosulphur compounds have been screened for their anticancer properties. Among the phenylpropanoids currently under clinical studies for anticancer activity, eugenol is a promising candidate. Eugenol is effective against cancers like breast, cervical, lung, prostate, melanomas, leukemias, osteosarcomas, gliomas, etc., as evident from preclinical investigations.
objectiveThe review aims to focus on cellular and molecular mechanisms of eugenol for cancer prevention and therapy.
methodsBased on predetermined criteria, various scholarly repositories, including PubMed, Scopus, and Science Direct were analyzed for anticancer activities of eugenol.
resultsDifferent biochemical investigations reveal eugenol inducing cytotoxicity, inhibiting phases of the cell cycles, programmed cell death, and auto-phagocytosis in studied cancer lines; thus, portraying eugenol as a promising anticancer molecule. A survey of current literature has unveiled the molecular mechanisms intervened by eugenol in exercising its anticancer role.
conclusionBased on the critical analysis of the literature, eugenol exhibits vivid signaling pathways to combat cancers of different origins. The reports also depict the advancement of novel nano-drug delivery approaches upgrading the therapeutic profile of eugenol. Therefore, eugenol nanoformulations may have enormous potential for both the treatment and prevention of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.